Price Alert

DiaMedica Therapeutics In... (DMAC)

NASDAQ: DMAC · Real-Time Price · USD

6.68

-0.37 (-5.25%)

At close: Oct 16, 2025, 3:59 PM

6.81

1.95%

After-hours: Oct 16, 2025, 04:23 PM EDT

-5.25% (1D)

Bid	6.57
Market Cap	345.28M
Revenue (ttm)	13.8M
Net Income (ttm)	-29.58M
EPS (ttm)	-0.69
PE Ratio (ttm)	-9.68
Forward PE	-9.26
Analyst	Strong Buy
Dividends	n/a

Ask	7.19
Volume	464,005
Avg. Volume (20D)	405,681
Open	7.05
Previous Close	7.05
Day's Range	6.66 - 7.24
52-Week Range	3.19 - 7.49
Beta	1.40
Ex-Dividend Date	n/a

About DMAC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DMAC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DMAC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

7 months ago

-13.02%

DiaMedica Therapeutics shares are trading lower fo... Unlock content with Pro Subscription

News

2 weeks ago · businesswire.com

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction a...

4 weeks ago · zacks.com

DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy?

Does DiaMedica Therapeutics, Inc. (DMAC) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago · zacks.com

After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright

DiaMedica Therapeutics, Inc. (DMAC) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, DMAC's 50-day simple moving average cross...

1 month ago · zacks.com

Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade

The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to a 100.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen...

1 month ago · zacks.com

What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now?

Does DiaMedica Therapeutics, Inc. (DMAC) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago · zacks.com

Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect?

The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to an 114.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme...

2 months ago · seekingalpha.com

DiaMedica: Interim Results Brings Study Expansions For DM199 In Preeclampsia

Positive interim phase 1a data for DM199 in preeclampsia establishes proof-of-concept and supports expansion to phase 1b and fetal growth restriction studies. DM199's mechanism targets key factors in ...

2 months ago · seekingalpha.com

DiaMedica Therapeutics Inc. (DMAC) Q2 2025 Earnings Call Transcript

DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Dietrich John Pauls - President, CEO & Director Julie Krop - Chief Medical O...